Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03742219 · ClinicalTrials.gov registry record · NA
Peru Longitudinal Study
A NA study, sponsored by Ohio University.
- Terminated
- Registry status
- NA
- Development phase
- 861
- Enrollment target
NCT03742219: Clinical Trial NA study, sponsored by Ohio University.
NCT03742219 is a NA study that was terminated before completion, run by Ohio University. The registered enrollment target is 861 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (39% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03742219, a NA study, was terminated before completion, sponsored by Ohio University.
- TERMINATED
- Registry status
- NA
- Development phase
- 861 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the change in disease prevalence over time in impoverished urban communities in Lima, Peru.
Primary Outcome
weight in kilograms will be utilized to determine body mass index
Interventions
- BEHAVIORAL Lifestyle Modification
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 861 participants |
| Start Date | 2017-06-05 |
| Est. Completion | 2020-03-01 |
| Phase | NA |
Why NCT03742219 stopped before completion
NCT03742219 is an interventional study that assigns participants to a tested intervention. The registered 861 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (39% lower).
The record links to 0 conditions, and to 1 intervention - of which Lifestyle Modification is the first listed.
NCT03742219 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03742219 about?
NCT03742219 is a clinical study titled "Peru Longitudinal Study". The purpose of this study is to evaluate the change in disease prevalence over time in impoverished urban communities in Lima, Peru.
What is the current status of trial NCT03742219?
This trial is currently terminated. It is a NA study. The enrollment target is 861 participants. The study started on 2017-06-05. Estimated completion is 2020-03-01.
What interventions are being tested in trial NCT03742219?
The interventions under investigation include: Lifestyle Modification (BEHAVIORAL).
Who is sponsoring clinical trial NCT03742219?
This trial is sponsored by Ohio University, which has 51 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03742219's enrollment target sits among peer trials
861 130th of 2000 higher than 1,871 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05914116 · 862 participants · Phase 1
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- NCT04541381 · 860 participants · NA
The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care
- NCT05211895 · 860 participants · Phase 3
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
- NCT06161025 · 860 participants · Phase 2
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI